ThromboGenics

FlandersBio on Twitter

VIB INKS QBASE+ GROUP LICENSING AGREEMENT WITH BIOGAZELLE: http://t.co/EkimyQQSZW

posted

Social Media

Life Sciences Database

in het nederlands

FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.

Website: http://www.thrombogenics.com
Email:
Phone: +32 16 75 13 10
FlandersBio Member
More address details

Business Focus

ThromboGenics is dedicated to developing and commercializing new pharmacologic treatments that address important unmet clinical needs in ophthalmology and oncology.

By delivering on this goal ThromboGenics intends to assist clinicians around the world to continually improve treatment for patients with sight threatening ophthalmic disorders and cancer.

Company Profile

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company’s lead product, JETREA^®(ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. In Europe, it has been approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA^® outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon’s net sales of JETREA^®. ThromboGenics and Alcon intend to share the costs equally of developing JETREA^® for a number of new vitreoretinal indications.

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), formerly referred to as TB-403, for the treatment of ophthalmic and oncology indications.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

Science & Technology or Services

The lead product, JETREA^®(ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013.Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.

The JETREA^®European Marketing Authorisation Application is currently under review by the European Medicines Agency. Following the positive CHMP recommendation, a final decision by the European Commission on European approval is expected in the first half of 2013.

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), formerly referred to as TB-403, for the treatment of ophthalmic indications.

Product description

Ocriplasmin:

JETREA^®(ocriplasmin) is a truncated form of human plasmin. In the US, JETREA^® is indicated for the treatment of symptomatic VMA. In Europe, JETREA^® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ≤ 400 microns. JETREA^® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.

JETREA^®has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.

JETREA’s Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA was generally well tolerated with most adverse events being transient and mild in severity.

TB-403, anti-PlGF (placental growth factor):

TB-403 is a monoclonal antibody against placental growth factor (PlGF). PlGF is a naturally occuring protein that belongs to the familiy of vascular endothelial growth factors (VEGF) that promote the formation of blood vessels.

Alliances

Rhein Minapharm (Egypt/Middle East)
ThromboGenics and Rhein Minapharm entered into a license agreement for manufacturing, clinical development and commercialization of THR-174, the next-generation derivative of Staphylokinase, in the Middle East, Africa and other countries comprising the MENA region. THR-174 is a recombinantly derived thrombolytic agent developed for treatment of acute myocardial infarction (heart attack).
Bharat Biotech International Limited (India)
ThromboGenics and Bharat Biotech International Limited entered into a license agreement for manufacturing, clinical development and commercialization of THR-100*, a novel variant of Recombinant Staphylokinase, in developing countries and certain industrialized countries. THR-100 is a thrombolytic agent developed for treatment of acute myocardial infarction (heart attack) and other vascular diseases based on its ability to dissolve blood clots.
* formerly known as Sak42D
BioInvent International AB (Sweden)
TB-403 (Anti-PlGF) as an anti-angiogenic agent for potential treatment of various diseases, including cancer, age-related macular degeneration, retinopathies and inflammation.
Millipore Corporation (USA)
ThromboGenics and Millipore Corporation entered into a license agreement under which ThromboGenics has licensed its technology for production of the proprietary stem cell culture medium marketed by Millipore as RESGRO(TM)*. The technology for producing RESGRO was originally developed by the ThromboGenics drug discovery team as part of its successful efforts to identify several of its drug discovery candidates currently in clinical trials.
* RESGRO and Chemicon are Milipore owned trademarks. RESGRO is also known as TX-WES Stem Cell Medium
Alcon (Switzerland)
ThromboGenics signed an important strategic deal with Alcon, the global leader in eye care, to commercialize ocriplasmin outside the U.S. ThromboGenics will receive up to €375 million in upfront and milestone payments plus royalties commensurate with a product that has successfully completed Phase III development and that has been filed for regulatory approval.

Academic

ThromboGenics has a wide range of agreements with numerous academic institutes that have significant research expertise in the vascular area, and from which the Company has in-licensed a number of the therapeutic programmes that it currently has under development. These academic institutes include:

Flanders Institute for Biotechnology (VIB)
The Company has an ongoing collaboration with the Center for Transgene Technology and Gene Therapy, a department of the VIB, on the pre-clinical characterisation of two of its programmes that were in-licensed from this institute, Anti-PlGF and PlGF.
Scientific Advisory Boards
In addition to the above collaborations, ThromboGenics has Advisory Boards for several of its advanced programmes (namely, the Microplasmin-Vitreoretinal Advisory Board, the Microplasmin-Stroke Advisory Board, the Anti-Factor VIII Advisory Board, and the Anti-PlGF Advisory Board).